QIAGEN and Novartis AG enter into a Supply Agreement targeting the field of siRNA
Aug 04 2003

QIAGEN and Novartis AG enter into a Supply Agreement targeting the field of siRNA

Venlo, The Netherlands, August 4, 2003 - QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA) today announced that it has entered into a supply agreement for siRNA molecules with Novartis AG (NYSE: NVS), a world leader in pharmaceuticals and consumer health based in Switzerland. Under the terms of this agreement QIAGEN will supply a genome wide siRNA library to Novartis. Financial terms were not disclosed.

"We are pleased that Novartis has chosen QIAGEN as its supplier for RNAi based gene silencing experiments", said Patrick Weiss, QIAGEN's Vice President of Gene Silencing and co-inventor of the TOM RNA chemistry. "This for QIAGEN significant agreement with Novartis demonstrates the outstanding benefits of QIAGEN's siRNA product and technology portfolio. The combination of QIAGEN's state of the art synthesis technologies, the chemistries based on TOM-amidites, which allow high cost efficiencies and our bioinformatics allow significant dimensions of quality, yield, time, cost and purity.

About Qiagen in RNAi:
RNAi is a powerful discovery tool of biomedical research using siRNA segments to turn off or "silence" a specific gene to study gene expression patterns as well as the impact of specific expression profiles directly on a cell or an entire organism. QIAGEN's patented siRNA synthesis based on TOM-amidites chemistry provides highest quality and purity of RNA oligonucleotides. QIAGEN's siRNA products combined with QIAGEN's robotic platforms, RNA transfection, -purification and -amplification technologies provide fully integrated solutions for gene silencing in the most dynamic area of today's functional genomics markets.

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).


Peer M. Schatz
Chief Financial Officer
+49 2103 2911 702
e-mail: peer.schatz@QIAGEN.com

Dr. Solveigh Mähler
Manager Investor Relations
+49 2103 2911 710
e-mail: solveigh.maehler@QIAGEN.com

Dr. Ulrich Schriek
VP Corporate Business Development
+49 2103 29 11238
e-mail: ulrich.schriek@QIAGEN.com


Share this page